Role of metabolic syndrome components in HIV-associated sensory neuropathy

AIDS

Volumn 23, Issue 17, 2009, Pages 2317-2322

  Ances, Beau M ^a   Vaida, Florin ^b   Rosario, Debralee ^c   Marquie Beck, Jennifer ^c   Ellis, Ronald J ^d   Simpson, David M ^e   Clifford, David B ^a   McArthur, Justin C ^f   Grant, Igor ^c   McCutchan, J Allen ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Highly active antiretroviral therapy; HIV; Metabolic syndrome; Sensory neuropathy

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

AGE; ARTERIAL PRESSURE; ARTICLE; BODY MASS; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REFLEX DISORDER; SELF REPORT; SENSORY NEUROPATHY; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; SENSATION DISORDERS;

EID: 70449362138     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328332204e     Document Type: Article

References (23)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
2. Fantoni M, Del Borgo C, Autore C, Barbaro G. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents. Ital Heart J 2002; 3:294-299.
3. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44:1892-1900.
4. Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008; 64:566-572.
5. Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999; 56:84-89.
6. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148-157.
7. Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 61:546-551.
8. Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, Epstein L, Kieburtz K. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58:1764-1768.
9. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004; 21:252-255.
10. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Dia-betologia 2001; 44:1148-1154.
11. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
12. Pi-Sunyer X. The metabolic syndrome: how to approach differing definitions. Med Clin North Am 2007; 91:1025-1040; vii.
13. Banegas JR, Segura J, Sobrino J, Rodriguez-Artalejo F, de la Sierra A, de la Cruz JJ, et al. Effectiveness of blood pressure control outside the medical setting. Hypertension 2007; 49:62-68.
14. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans-a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142-161. (Pubitemid 40066429)
15. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341-350.
16. Gonzalez-Duarte A, Robinson-Papp J, Simpson DM. Diagnosis and management of HIV-associated neuropathy. Neurol Clin 2008; 26:821-832; x.
17. Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr Opin Neurol 2003; 16:403-409.
18. Swanson B, Zeller JM, Paice JA. HIV-associated distal symmetrical polyneuropathy: clinical features and nursing management. J Assoc Nurses AIDS Care 1998; 9:77-80.
19. Dorsey SG, Morton PG. HIV peripheral neuropathy: pathophy-siology and clinical implications. AACN Clin Issues 2006; 17:30-36.
20. Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006; 66: 1679-1687.
21. Villelabeitia-Jaureguizar K, Rivas-Gonzalez P, Ibarra-Luzar JI, Fernandez-Garcia C, Goyenechea-Herrero A, Frenadas Bravo-Rueda A, Gorgolas Hernandez-Mora M. Clinical and subclini-cal neuropathy in patients with human immunodeficiency virus receiving antiretroviral therapy. Rev Neurol 2006; 42:513-520.
22. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson DM, Alexander T, et al. Continued high prevalence and adverse clinical impact of HIV-associated sensory neuropathy in the era of combination antiretroviral therapy (CART): The CHARTER study. Arch Neurol (in press).
23. Kassem HS, Azar ST, Zantout MS, Sawaya RA. Hypertriglycer-idemia and peripheral neuropathy in neurologically asymptomatic patients. Neuro Endocrinol Lett 2005; 26:775-779